

NEWS RELEASE

Teijin Regenet Joins ACGMP, Global Alliance of CGT CDMOs, as a Founding Member

Tokyo, October 29, 2026 – [Teijin Regenet Co., Ltd.](#), a Teijin Group company specializing in regenerative medicine CDMO services, announced today that it entered into an agreement on September 25, 2026, to join the Alliance of CGT Manufacturing Partners (ACGMP), a global alliance of CDMOs in the cell and gene therapy (CGT) field, as a founding member.

Through its participation in ACGMP, Teijin Regenet will strengthen its global development and manufacturing network and contribute to accelerating the commercialization of CGT and expanding patient access to innovative treatments.

Research and development of CGT has been advancing globally. At the same time, increasing manufacturing complexity and more stringent quality and regulatory requirements have driven growing demand for specialized CDMOs. As therapy developers expand their activities globally, the need for manufacturing, quality and regulatory support across multiple regions continues to increase.

ACGMP was established to bring together specialized CDMOs across different countries and regions, enabling therapy developers to access manufacturing partners with the technical expertise and regional infrastructure required for their programs.

Through joint promotional activities, client referrals and collaborative projects, ACGMP aims to enhance the visibility and credibility of its member companies. The alliance also plans to develop common tools for quality management and technology transfer and promote collaboration among member companies' technical and quality teams.

By joining ACGMP, Teijin Regenet will enhance its support capabilities for CGT developers in Japan and overseas while strengthening collaboration and knowledge sharing with alliance members.

In line with the Teijin Group's med-term management strategy based on the concept of "Suriawase × Kumiawase," Teijin Regenet will leverage internal and external technologies, expertise and networks to create new value and contribute to the commercialization and wider adoption of innovative CGT.

About the Alliance of CGT Manufacturing Partners (ACGMP)

The Alliance of CGT Manufacturing Partners (ACGMP) is a global alliance of independent specialist CDMOs focused on CGT. Its founding members are Cell Therapies (Melbourne, Australia), eXmoor Pharma (United Kingdom), Nucleon Therapeutics (Hyderabad, India), Siam Bioscience (Bangkok, Thailand), SCTbio (Prague, Czech Republic), Teijin Regenet (Tokyo, Japan), and Xellera (Hong Kong).

Through a network of specialist CDMOs spanning Europe, Asia and Oceania, ACGMP helps therapy developers access manufacturing partners with the technical capabilities and regional operational infrastructure required for their development programs. The alliance aims to support the development and manufacturing of CGT across multiple regions through joint outreach activities, client referrals, and collaboration in quality systems and technology transfer.

Founding Members

Seven members across seven regions, founded by eXmoor Pharma, SCTbio and Cell Therapies



About Teijin Regenet

[Teijin Regenet Co., Ltd.](https://www.teijin.co.jp/en/teijin-regenet), established in 2023, is a Teijin Group company dedicated exclusively to providing contract development and manufacturing services for Cell and Gene Therapy and Regenerative Medicines (CGT/RM). By leveraging its industrialization platform for CGT and RM products and its manufacturing facilities in Kashiwa, Chiba Prefecture and Iwakuni, Yamaguchi Prefecture, the company provides one-stop CDMO services ranging from process development to commercial manufacturing.

Press Contact

Corporate Communication Department
Teijin Limited
E-mail: pr@teijin.co.jp